Views: 0 Author: Site Editor Publish Time: 2022-07-11 Origin: Site
The world is once again facing a new wave of outbreaks.
The new subtypes of Omicron BA.4 and BA.5 are causing a new wave of infections in Europe. Among them, France is being challenged by the 7th wave of the new crown outbreak. According to CCTV news, the number of new cases in France exceeded 200,000 in a single day, and 12% of the confirmed cases are "repeat infections". This means that Omicron BA.4 and BA.5 have shown strong "immune escape" characteristics. In addition, the epidemic in Spain is worsening, with the number of confirmed cases in the 60+ age group on the rise, and the health care system in many places is already under great pressure.
As a new wave of NCC infections sweeps the world again, the "long-term NCC" patients are also a hot topic of discussion. According to the latest estimates from the CDC, about 7.5 percent of U.S. adults have symptoms of "long-term neonatal" including dizziness and chest pain, and a new CNBC report says scientists, doctors and public health officials are concerned that millions of Americans could suffer long-term health complications from neonatal infections.
At the same time, the U.S. faces the challenge of a monkeypox epidemic. According to the CDC, as of July 8, there have been more than 700 confirmed cases of monkeypox across the U.S., with California and New York having the most. Several U.S. media outlets have angrily criticized the U.S. government for its ineffective response to the monkeypox epidemic, which has led to the rapid spread of the epidemic.
European epidemic emergency
In the face of the raging Omicron new subtypes BA.4 and BA.5, the European epidemic situation is once again urgent.
Among them, France has set off the seventh wave of new crown infection wave. According to CCTV news reports, the number of new confirmed cases in France on a single day once exceeded 200,000 cases, and during the period from June 29 to July 5, France had an average of 119,000 new infections per day, an increase of 80% compared to the previous week. The actual rate of infection in France may be much higher than the current figure due to the limited number of tests. France's new health minister Francois Braun told the Council of Ministers that the new variants of BA.4 and BA.5 have become the main strains in France, leading to a "resurgence" of the epidemic in France.
With the number of infections rising rapidly, France's health care system is again under pressure. According to the latest forecast released by the Pasteur Institute, the number of hospitalizations related to the new strain will increase further in the coming days, with about 1,700 admissions per day expected on July 18, a 70% jump compared to the current number of hospitalizations, with the number of patients requiring intensive care climbing to about 160 per day from the current 100 new patients.
What is alarming is the significant increase in the number of "repeat infections" of new crowns in France in the face of the stronger immune escapes of Omicron BA.4 and BA.5. According to the weekly report released by the French Public Health Agency, 12% of the current confirmed cases of NICs in France are "repeat infections", a significant increase compared to the previous 4.1%.
In particular, the French Public Health Agency defines "repeat infections" as patients who test positive for NICs again at least 60 days after their first infection.
In this regard, medical experts believe that because omicron BA.4 and BA.5 exhibit strong "immune escape" properties, it is more likely to cause infection in people who have been infected or vaccinated against Neocon. The French Public Health Agency has warned that, given the accelerated spread of NIV observed in France and the characteristics of Omicron BA.4 and BA.5, it is expected that the number of "repeat infections" will continue to rise in the coming weeks.
In addition, according to Spanish media reports, the outbreak of New Coronavirus in Spain has recently shown a worsening trend due to the rapid spread of BA.4 and BA.5 mutant strains. The number of new coronary pneumonia infections in the country's population over 60 years of age is on the rise, and hospitalizations continue to increase, putting the health care system under enormous pressure in many areas.
Experts emphasize that vaccines and booster shots remain the best defense against NCCV. This fall, a vaccine against Omicron may be available in the United States.
With the outbreak of Omicron subvariant BA.4/5 driving a significant rebound on the European continent, the European Centre for Disease Control and Prevention (ECDC) and the European Medicines Agency (EMA) issued an urgent joint statement on Monday updating recommendations for a "fourth" dose of the Neocon vaccine.
The European Medicines and Epidemiology Agency (EMA) recommended that countries use all available vaccines to give another dose to people at high risk (over 60 years old) who have received a booster for at least four months. Both agencies had previously recommended only a "fourth dose" for people 80 years of age and older.
"Long-term Newcastle" is a hot topic
As a new wave of new coronary infections sweeps the world again, there is a lot of discussion about "long-term new coronary" patients.
"Long-term neoconiosis is also known as "post-neoconiosis syndrome" or "post-neoconiosis". The World Health Organization defines a clinical case as one in which at least one symptom develops within three months of diagnosis and cannot be explained by another diagnosis.
According to the latest estimates from the CDC, about 7.5% of U.S. adults have symptoms of "prolonged neonatal coronary", including dizziness and chest pain.
In addition, a study by the Harvard School of Public Health revealed that about 80 percent of the more than 40,000 patients
observed suffered from at least one sequelae four weeks after diagnosis. The five most common sequelae were extreme fatigue, headache, attention deficit, hair loss and breathing problems. In addition, 65% of patients with "long-term neonatal" had viral spike proteins in their blood that were still present up to 12 months after they were first diagnosed.
Like other viral sequelae, the symptoms of "long term neonatal" can vary from person to person. For some patients, it can cause neurological problems, such as brain fog; for others, it can cause digestive symptoms, such as diarrhea; and studies have shown that a small percentage of patients can develop further blood clots, strokes, diabetes and kidney damage.
Scientists, doctors and public health officials are concerned that millions of Americans could suffer long-term health complications from contracting the new crown, according to a new CNBC report.
Among them, a large number of vulnerable groups, such as children, have fallen victim to the "long-term new crown" or secondary outbreak. Since the new crown pandemic, 13.8 million children in the United States have been infected with the new crown virus, and there has been a massive rebound recently. According to the American Academy of Pediatrics, 76,000 new cases of NCC in children were reported in the United States during the week of June 27 to July 3 alone.
Massimo, a top Italian epidemiologist, analyzed the secondary risks of "long-term neointima" from a professional perspective and cited the latest clinical findings in Germany from the latest British study in the Journal of Hepatology, a sub-publication of The Lancet, indicating that there is a high probability that outbreaks of hepatitis in children are due to the effects of long-term neointima.
The main reason for the relatively slow progress in drug development for "long-term neonatal" is that developing therapeutics for patients with "long-term neonatal" is much more complex than developing acute treatment and vaccine regimens for neonatal viruses.
Ted Ross, global director of vaccine development at Cleveland Clinic, believes that effective treatments for "long-term neocon" may have to wait several more years. In the meantime, the threat of "long-term neostrike" will continue to exist as long as the neostrike virus remains in the population.
Monkeypox outbreak spreads in the United States
In the meantime, the U.S. faces the challenge of a monkeypox epidemic.
According to the latest NBC report, as of July 8, the United States has more than 700 confirmed cases of monkeypox, including California and New York State, the most, the epidemic is spreading like a snowball. Experts point out that the actual number may be much higher than the official statistics.
In addition, according to the latest WHO statistics, 58 countries and regions worldwide have reported more than 6,000 cumulative cases of monkeypox, and there may still be a large number of cases undetected. Currently more than 80% of the global monkeypox cases come from Europe, which has become the center of the current monkeypox epidemic.
In the face of the rapidly spreading monkeypox epidemic, the U.S. government is increasing monkeypox testing and vaccine distribution efforts.
The U.S. Department of Health and Human Services began distributing 144,000 doses of vaccine approved for use against monkeypox and smallpox viruses on July 11. In addition, the CDC announced that LabCorp, an independent U.S. medical laboratory, has opened a laboratory in North Carolina to conduct monkeypox testing with a capacity of approximately 10,000 doses per week, and that four other commercial laboratories will be operational in the coming weeks.
The U.S. media, however, is not buying this series of moves. The New York Times published an article on July 8 angrily disliking the U.S. government's poor response to the monkeypox epidemic, which led to the rapid spread of the epidemic, and the poor performance of the U.S. government in response to the early stages of the New Crown pandemic is being repeated.
The New York Times pointed out that the Biden administration's ineffectiveness in fighting the monkeypox epidemic is reflected in several aspects. On the one hand, the United States was the first case of monkeypox reported in May this year, but it was not until July that effective testing could be conducted, resulting in a serious underestimation of the actual number of infections. On the other hand, the monkeypox vaccine has been facing shortages and will likely continue for several months, leading to frequent closures of major monkeypox vaccination sites.
The slow response to monkeypox by the U.S. government is reminiscent of the early days of the New Guinea pandemic and has raised concerns that the U.S. is ill-prepared to deal with pandemic diseases.
In fact, monkeypox is not a new virus, and the outbreaks it causes are relatively easy to extinguish. The first is that the virus requires close contact to be effectively transmitted; the second is that the United States already has the means of detection and vaccine before the monkeypox outbreak.
In response, U.S. epidemiologist Anne Rimone said that there is a systemic problem with the U.S. public health system in responding to outbreaks, so why is it so difficult to respond to a known pathogen?
